Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as QXL138AM Injection every 2 weeks by IV Infusion
QXL138AM every 2 weeks by Infusion · 1 trial · 9 indications
Record all safety events during study including AEs, SAEs, DLTs, AESIs.
| Arm | Type | Description |
|---|---|---|
| Phase 1a Dose Escalation in Solid Tumors - Part A1 | EXPERIMENTAL | Dose escalation of QXL138AM in participants with locally advanced un-resectable and/or metastatic solid tumors. |
| Phase 1a Dose Escalation in Multiple Myeloma - Part A2 | EXPERIMENTAL | Dose escalation of QXL138AM in participants with multiple myeloma. |
| Phase 1b Dose Expansion in Solid Tumors - Part B1 | EXPERIMENTAL | Dose expansion in solid tumors using the recommended dose for expansion from Part A1 |
| Phase 1b Dose Expansion in Multiple Myeloma - Part B2 | EXPERIMENTAL | Dose expansion in Multiple Myeloma using the recommended dose for expansion from Part A2 |
| Name | Type | Description |
|---|---|---|
| QXL138AM Injection every 2 weeks by IV Infusion | BIOLOGICAL | masked immuno-cytokine comprised of an anti-CD138 IgG1 antibody fused to human interferon alpha 2a |
Inclusion Criteria: 1. Participants with Solid Tumors * Histopathologically confirmed diagnosis of an advanced, unresectable, or metastatic solid tumor (ovarian, pancreatic, urothelial, renal, hepatocellular, gastrointestinal (GI), lung, prostate, and breast cancer). * Have progressed despit...
Top 20 of 58 competitors